PharyngitisPhase 1NCT06859281

Safety, Tolerability, and Pharmacokinetic Profile of Grammidin, a Metered Dose Topical Spray in Healthy Volunteers

A Phase 1 study testing Grammidin neo and Grammidin, a metered dose topical spray in people with Pharyngitis, run by Valenta Pharm JSC at 1 site in Russia.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

This study aims to evaluate the safety, tolerability, and pharmacokinetic profile of the Grammidin, a metered dose topical spray, compared to Grammidin lozenges following single administration in healthy volunteers . Read more about this study

Who is it for?: Ages 18 to 45 yearsHealthy volunteers can take part
Conditions the study is for: Pharyngitis
What is being tested?: Grammidin neo and Grammidin, a metered dose topical spray
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 24 participants
Where: 1 siteRussia
Study dates: 10 Dec 2024to 1 Dec 2026
Phase: Phase 1
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 45 years
All sexes
Healthy volunteers accepted
Adult

Who may be able to join

Voluntarily and personally signed informed consent form by a healthy volunteer obtained prior to the conduct of any study-related procedure;
Males and females aged 18 to 45 years (inclusive);
Verified healthy status as demonstrated by the absence of clinically significant abnormalities in medical history, physical examination, laboratory tests, and other diagnostic procedures specified in the protocol;
Blood pressure (BP) level: systolic blood pressure (SBP) from 99 to 129 mm Hg (inclusive), diastolic blood pressure (DBP) from 70 to 89 mm Hg (inclusive);
Heart rate (HR) from 60 to 89 beats per minute (inclusive);
Respiratory rate (RR) from 12 to 20 breaths per minute (inclusive);

Show all 41Show fewer

Body temperature from 36.0°C to 36.9°C (inclusive);
Body mass index (BMI) between 18.5 kg/m² and 30 kg/m², with a minimum body weight of ≥ 55 kg for men and ≥ 45 kg for women;
Consent to use adequate contraceptive methods throughout the study and for 30 days after its completion, with a negative urine pregnancy test result for women of childbearing potential.
Non-Inclusion Criteria:
Clinically significant allergic history;
Hypersensitivity to active and/or excipient substances in the investigational drug and comparator drug in the medical history;
Drug intolerance to active and/or excipient substances in the investigational drug and comparator drug in the medical history;
Chronic diseases of the kidneys, liver, gastrointestinal tract (GIT), cardiovascular, lymphatic, respiratory, nervous, endocrine, musculoskeletal, urogenital, and immune systems, as well as skin, hematopoietic organs, and the eye;
Erosive-ulcerative lesions of the oral mucosa (aphthous stomatitis, mechanical trauma due to dental diseases, herpes lesions, and any other condition resulting in compromised integrity of the oral mucosa);
Surgical interventions on the GIT in the medical history (except for appendectomy performed at least 1 year prior to screening);
Diseases/conditions that, in the investigator's judgment, may affect the absorption, distribution, metabolism, or excretion of the investigational drugs;
Acute infectious diseases less than 4 weeks before screening;
Use of medications (drugs) that significantly affect hemodynamics and drugs affecting liver function (barbiturates, omeprazole, cimetidine, etc.) less than 2 months before screening;
Regular use of medications less than 2 weeks before screening and single use of medications less than 7 days before screening (including over-the-counter medications, vitamins, dietary supplements, herbal medicines);
Blood or plasma donating within 3 months prior to screening;
Use of hormonal contraceptives (in women) within 2 months prior to screening;
Use of depot injections of any medications within 3 months prior to screening;
Pregnancy or lactation; positive urine pregnancy test result for women of childbearing potential;
Female subjects of childbearing potential who had unprotected sexual intercourse with an unsterilized male partner within 30 days prior to administration investigational drugs;
Participation in another clinical study within 3 months prior to screening or concurrently with this study;
Consumption of more than 10 alcohol units per week (1 unit of alcohol is equivalent to 500 ml of beer, 200 ml of wine, or 50 ml of strong alcoholic beverages) in the last month before inclusion in the study or a history of alcoholism, drug addiction, or substance abuse;
Smoking more than 10 cigarettes per day currently or smoking that amount in the past 6 months prior to screening; unwillingness to refrain from smoking during hospitalization;
Consumption of alcohol, caffeine, and xanthine-containing products within 7 days prior to taking investigational drugs;
Consumption of citrus fruits, cranberries, rose hips and products containing them, or preparations/products containing St. John's wort within 7 days prior to taking investigational drugs;
Dehydration due to diarrhea, vomiting, or other causes within the last 24 hours prior to taking investigational drugs;
Positive blood test for antibodies to human immunodeficiency virus (HIV) types 1 and 2, antibodies to Treponema pallidum antigens, hepatitis B surface antigen (HBsAg), antibodies to hepatitis C virus antigens during screening;
Positive rapid test for SARS-CoV-2 at screening;
ECG abnormalities in medical history and/or during screening;
Positive urine test for narcotic substances and potent medications during screening;
Positive breath alcohol test result during screening;
Planning hospitalization during the study period for any reason other than hospitalization specified in this protocol;
Inability or unwillingness to comply with protocol requirements, perform procedures prescribed by the protocol, or adhere to dietary and activity restrictions;
Membership in a vulnerable population? including but not limited to students of medical, pharmaceutical and dental educational institutions, junior staff of clinics and laboratories, employees of pharmaceutical companies, military personnel, prisoners, residents of care facillities, individuals with low income or unemployed, members of ethnic minorities, homeless persons, vagrants, refugees, individuals under guardianship or conservatorship, ndividuals unable to provide informed consent and law enforcement personnel;
Dental procedures performed within 3 weeks prior to screening;
Other conditions that in the judgment of the Investigator may prevent volunteer inclusion in the study or lead to premature withdrawal from the study including adherence to fasting or special diets (e.g., vegetarianism, veganism, salt restriction) or special lifestyles (night work, extreme physical exertion).

Who cannot join

Withdrawal of the volunteer from further participation in the study;
Non-compliance by the volunteer with the study participation rules (missed study procedures, self-administration of drugs prohibited in the study, violation of dietary and lifestyle restrictions, etc.);
Emergence of reasons/situations during the study that threaten the safety of the volunteer (e.g., hypersensitivity reactions, etc.);
Volunteers selected for participation in the study who do not meet inclusion/exclusion criteria;
Development of a severe adverse event (SAE) in the volunteer during the study;
The volunteer undergoes or requires treatment that may affect the pharmacokinetic parameters (PKP) of the investigational drugs;

Show all 13Show fewer

Missed collection of 2 or more consecutive blood samples or 3 or more blood samples within one study period;
Occurrence of vomiting/diarrhea within 6 hours after taking the investigational drug;
Positive urine test for narcotic substances and potent medications;
Positive breath test for alcohol vapors;
Positive pregnancy test result in women;
Positive SARS-CoV-2 test result;
Emergence of other reasons during the study that prevent conducting the study according to the protocol.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Russia1 site, 1 recruiting

Limited Liability Company "Research Center Eco-Safety"
Saint Petersburg, 196143
Viktoria Dedkova, MD, +7-812-500-52-03, dedkova_va@ecosafety.ru
Recruiting

Other trials in Russia

About this study

Official title: An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of the Drug Grammidin, a Metered Dose Topical Spray Following Single Administration in Healthy Volunteers

Conditions: Pharyngitis
Being tested: Grammidin neo, Grammidin, a metered dose topical spray
Medical subject headings: Pharyngitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Grammidin neoDrug
Also called gramicidin s, cetylpyridinium chloride
Grammidin neo, lozenges, 1 lozenge to be taken once under fed conditions.
Grammidin, a metered dose topical sprayDrug
Also called gramicidin s, cetylpyridinium chloride
Grammidin, a metered dose topical spray, 4 sprays to be taken once under fed conditions.

Study groups in NCT06859281
Study group	Role	What they receive
RT sequence: Grammidin neo, lozenges, followed by Grammidin, a metered dose topical spray	Experimental	RT sequence where R is Grammidin neo, lozenges and T is Grammidin, a metered dose topical spray Receives: Drug: Grammidin neo; Drug: Grammidin, a metered dose topical spray
TR sequence: Grammidin, a metered dose topical spray, followed by Grammidin neo, lozenges	Experimental	TR sequence where T is Grammidin, a metered dose topical spray and R is Grammidin neo, lozenges Receives: Drug: Grammidin neo; Drug: Grammidin, a metered dose topical spray

What is being measured

The primary outcome is the main question the study is designed to answer.

Pharmacokinetics - Cmax
Maximum plasma concentration (Cmax) of gramicidin S and cetylpyridinium chloride. The same analytes would be used for other pharmacokinetic measures listed below.
Measured: From 0 to 24 hours after each drug intake.
Pharmacokinetics - tmax
Time to reach Cmax (tmax)
Measured: From 0 to 24 hours after each drug intake.
Pharmacokinetics - AUC0-t
Area under the plasma concentration-time curve from time 0 to t (AUC0-t)
Measured: From 0 to 24 hours after each drug intake.
Pharmacokinetics - AUC0-inf
Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf)
Measured: From 0 hours after each drug intake (extrapolated to infinity).
Pharmacokinetics - AUCextr
Extrapolated AUC defined as (AUC0-inf - AUC0-t)/AUC0-inf
Measured: From 0 hours after each drug intake (extrapolated to infinity).
Pharmacokinetics - t1/2
Elimination half-life (t1/2)
Measured: From 0 to 24 hours after each drug intake.
Pharmacokinetics - kel
Elimination constant (kel)
Measured: From 0 to 24 hours after each drug intake.
Pharmacokinetics - MRT
Mean residence time (MRT)
Measured: From 0 to 24 hours after each drug intake.
Pharmacokinetics - Vd
Volume of distribution
Measured: From 0 to 24 hours after each drug intake.
Pharmacokinetics - CL
Clearance (CL)
Measured: From 0 to 24 hours after each drug intake.
Pharmacokinetics - number of terminal timepoints
Number of points in the terminal logarithmic phase used to estimate the terminal elimination rate constant
Measured: From 0 to 24 hours after each drug intake.

Secondary outcomes (55)

Adverse event type
Adverse events will be assessed by complaints, results of physical examination, results of heart rate and blood pressure assessment, results of respiratory rate assessment, body temperature, laboratory monitoring (clinical blood count, biochemical blood count, urinalysis), electrocardiography; adverse events will be classified in accordance to MedDRA.
Measured: From screeninig (days -14 to -1) to the end of study (day 15 ± 1)
Adverse event number
Number of adverse events registered during the study
Measured: From screeninig (days -14 to -1) to the end of study (day 15 ± 1)
Adverse event severety
Severity of adverse events registered during the study
Measured: From screeninig (days -14 to -1) to the end of study (day 15 ± 1)
Drop-outs associated with adverse events
The number of cases of early termination of participation in the study due to the development of adverse events and/or serious adverse events associated with the study drug
Measured: From screeninig (days -14 to -1) to the end of study (day 15 ± 1)
Volunteer complaints
Description of complaints, recieved from volunteer
Measured: From screeninig (days -14 to -1) to the end of study (day 15 ± 1)
Physical examination results - cardiovascular system
An assessment of the condition of the cardiovascular system on physical examination (normal condition or list of abnormal conditions, if any)
Measured: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Physical examination results - respiratory system
An assessment of the condition of the respiratory system on physical examination (normal condition or list of abnormal conditions, if any)
Measured: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Physical examination results - digestive tract
An assessment of the condition of the digestive tract on physical examination (normal condition or list of abnormal conditions, if any)
Measured: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Physical examination results - endocrine system
An assessment of the condition of the endocrine system on physical examination (normal condition or list of abnormal conditions, if any)
Measured: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Physical examination results - musculoskeletal system
An assessment of the condition of the musculoskeletal system on physical examination (normal condition or list of abnormal conditions, if any)
Measured: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Safety and Tolerability: physical examination results - nervous system
An assessment of the condition of the nervous system on physical examination (normal condition or list of abnormal conditions, if any)
Measured: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Physical examination results - sensory systems
An assessment of the condition of the sensory systems on physical examination (normal condition or list of abnormal conditions, if any)
Measured: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Physical examination results - skin/visible mucous membranes
An assessment of the condition of the skin/visible mucous membranes on physical examination (normal condition or list of abnormal conditions, if any)
Measured: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Vital signs - systolic blood pressure
Systolic blood pressure (SBP, mmHg)
Measured: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Vital signs - diastolic blood pressure
Diastolic blood pressure (DBP, mmHg)
Measured: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Vital signs - heart rate
Heart rate (HR, bpm)
Measured: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Vital signs - body temperature (Celsius temperature scale)
Body temperature (Celsius temperature scale)
Measured: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
12-lead electrocardiogram (ECG) - heart rate
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: heart rate (beats per minute)
Measured: Screeninig (days -14 to -1), day 1, 2, 8, 9, 15 ± 1
12-lead electrocardiogram (ECG) - PQ interval
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: PQ interval (is the period, measured in milliseconds, that extends from the beginning of the P wave (the onset of atrial depolarization) until the beginning of the QRS complex)
Measured: Screeninig (days -14 to -1), day 1, 2, 8, 9, 15 ± 1
12-lead electrocardiogram (ECG) - QRS complex
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: QRS complex (the QRS complex is the combination of three of the graphical deflections seen on a typical electrocardiogram)
Measured: Screeninig (days -14 to -1), day 1, 2, 8, 9, 15 ± 1
12-lead electrocardiogram (ECG) - corrected QT interval
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: corrected QT interval (distance from the beginning of the QRS complex to the end of the T wave)
Measured: Screeninig (days -14 to -1), day 1, 2, 8, 9, 15 ± 1
Clinical blood test - hemoglobin
Hemoglobin (g/L)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - hematocrit
Hematocrit (%)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - red blood cell count
Red blood cell count (cells/L)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - platelet count
Platelet count (cells/L)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - leukocyte count
Leukocyte count (cells/L)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - erythrocyte sedimentation rate
Erythrocyte sedimentation rate (mm/h)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - myelocytes
Leukocyte formula (myelocytes, %)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - band neutrophils
Leukocyte formula (band neutrophils, %)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - segmented neutrophils
Leukocyte formula (segmented neutrophils, %)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - eosinophils
Leukocyte formula (eosinophils, %)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - basophils
Leukocyte formula (basophils, %)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - monocytes
Leukocyte formula (monocytes, %)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - lymphocytes
Leukocyte formula (lymphocytes, %)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Urinalysis - specific gravity
Specific gravity of the urine
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Urinalysis - color
Color of the urine
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Urinalysis - transparency
Transparency of the urine
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Urinalysis - pH
pH of the urine
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Urinalysis - protein
Protein concentration (g/L)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Urinalysis - glucose
Glucose concentration (mmol/L)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Urinalysis - red blood cells
Red blood cell content (number in sight)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Urinalysis - white blood cells
White blood cell content (number in sight)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Urinalysis - epithelial cells
Epithelial cell content (number in sight)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Urinalysis - casts
Presence of casts (Yes/No)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Urinalysis - mucus
Presence of mucus (Yes/No)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Urinalysis - bacteria
Presence of bacteria (Yes/No)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Urinalysis (microscopy)
Microscopy of urine sediment is performed if it is present
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Blood chemistry - glucose
Glucose concentration (mmol/L)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Blood chemistry - cholesterol
Total cholesterol concentration (mmol/L)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Blood chemistry - protein
Total protein concentration (g/L)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Blood chemistry - bilirubin
Total bilirubin concentration (micromol/L)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Blood chemistry - creatinine
Creatinine concentration (micromol/L)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Blood chemistry - alkaline phosphatase
Alkaline phosphatase activity (U/L)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Blood chemistry - alanine transaminase
Alanine transaminase activity (U/L)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Blood chemistry - aspartate transaminase
Aspartate transaminase activity (U/L)
Measured: Screeninig (days -14 to -1), day 2, 9, 15 ± 1

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

10 Dec 20241 Dec 2026

First posted5 Mar 2025
Study start10 Dec 2024
Primary completion1 Dec 2026 (estimated)
Study completion1 Dec 2026 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for PharyngitisStudies of the same condition, open and under way.
More trials run by Valenta Pharm JSCThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 1
Primary purpose: Other
Allocation: Randomised
Intervention model: Crossover
Masking: None (open label)
Enrolment: 24 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06859281
Sponsor's protocol ID: GRM-01-05-2024
Status last verified: Jul 2025
First submitted: 17 Feb 2025
Last updated: 10 Jul 2025
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Interested in taking part?

Each site lists its own contact. Pick the site nearest to you.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Not yet recruiting
Intracuff Dexmedetomidine Versus Alkalinized Lidocaine for Peri-Extubation Cough and Hemodynamic Responses in Elderly Patients
Airway Complication of Anesthesia, Hemodynamic Instability
RecruitingPhase 4
A Single Dose of Intravenous Penicillin as an Adjunct to Oral Penicillin in the Treatment of Acute Tonsillitis, Peritonsillar Phlegmon, and Peritonsillar Abscess
Acute Tonsillitis, Peritonsillar Abscess
Recruiting
Pharyngeal Mucosal Conditioning to Prevent Postoperative Sore Throat in Septoplasty Patients With Severe Nasal Obstruction
Postoperative Sore Throat, Nasal Obstruction
RecruitingObservational study
A Multicenter Evaluation of SalivIQ™ Strep A for Detecting Group A Streptococcus From Saliva and Throat Swabs in Patients With Acute Pharyngitis
Streptococcal Pharyngitis, Group A Streptococcal Infection
Not yet recruiting
Enhanced Telemedicine in Primary Care for Acute Respiratory Tract Infections Study
Acute Respiratory Tract Infection, Ear Infection

All Pharyngitis trials

Study at a glance

From the registry record, last updated by the sponsor on 10 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of the Drug Grammidin, a Metered Dose Topical Spray Following Single Administration in Healthy Volunteers
ClinicalTrials.gov ID: NCT06859281
Acronym / sponsor ID: GRM-01-05-2024
Conditions: Pharyngitis
Phase: Phase 1
Study type: Interventional
Recruitment status: Recruiting
Enrolment: 24 participants (estimated)
Lead sponsor: Valenta Pharm JSCIndustry (pharma, biotech, devices)
Study start: 10 Dec 2024 (actual)
Primary completion: 1 Dec 2026 (estimated)
Study completion: 1 Dec 2026 (estimated)
First posted: 5 Mar 2025 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Other
Allocation: Randomised
Intervention model: Crossover
Masking: None (open label)
Number of arms: 2

Arm	Type	Receives
RT sequence: Grammidin neo, lozenges, followed by Grammidin, a metered dose topical spray	Experimental	Drug: Grammidin neo, Drug: Grammidin, a metered dose topical sprayRT sequence where R is Grammidin neo, lozenges and T is Grammidin, a metered dose topical spray
TR sequence: Grammidin, a metered dose topical spray, followed by Grammidin neo, lozenges	Experimental	Drug: Grammidin neo, Drug: Grammidin, a metered dose topical sprayTR sequence where T is Grammidin, a metered dose topical spray and R is Grammidin neo, lozenges

Who may qualify

Ages: 18 to 45 years
Sex: All
Healthy volunteers: Accepted
Age groups: Adult

Key inclusion criteria (41 listed)

Voluntarily and personally signed informed consent form by a healthy volunteer obtained prior to the conduct of any study-related procedure;
Males and females aged 18 to 45 years (inclusive);
Verified healthy status as demonstrated by the absence of clinically significant abnormalities in medical history, physical examination, laboratory tests, and other diagnostic procedures specified in the protocol;
Blood pressure (BP) level: systolic blood pressure (SBP) from 99 to 129 mm Hg (inclusive), diastolic blood pressure (DBP) from 70 to 89 mm Hg (inclusive);
Heart rate (HR) from 60 to 89 beats per minute (inclusive);

Key exclusion criteria (13 listed)

Withdrawal of the volunteer from further participation in the study;
Non-compliance by the volunteer with the study participation rules (missed study procedures, self-administration of drugs prohibited in the study, violation of dietary and lifestyle restrictions, etc.);
Emergence of reasons/situations during the study that threaten the safety of the volunteer (e.g., hypersensitivity reactions, etc.);
Volunteers selected for participation in the study who do not meet inclusion/exclusion criteria;
Development of a severe adverse event (SAE) in the volunteer during the study;

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Grammidin neoAlso: gramicidin s, cetylpyridinium chlorideGrammidin neo, lozenges, 1 lozenge to be taken once under fed conditions.	Drug	RT sequence: Grammidin neo, lozenges, followed by Grammidin, a metered dose topical spray, TR sequence: Grammidin, a metered dose topical spray, followed by Grammidin neo, lozenges
Grammidin, a metered dose topical sprayAlso: gramicidin s, cetylpyridinium chlorideGrammidin, a metered dose topical spray, 4 sprays to be taken once under fed conditions.	Drug	RT sequence: Grammidin neo, lozenges, followed by Grammidin, a metered dose topical spray, TR sequence: Grammidin, a metered dose topical spray, followed by Grammidin neo, lozenges

Primary outcome

Pharmacokinetics - Cmax
Time frame: From 0 to 24 hours after each drug intake.
Maximum plasma concentration (Cmax) of gramicidin S and cetylpyridinium chloride. The same analytes would be used for other pharmacokinetic measures listed below.
Pharmacokinetics - tmax
Time frame: From 0 to 24 hours after each drug intake.
Time to reach Cmax (tmax)
Pharmacokinetics - AUC0-t
Time frame: From 0 to 24 hours after each drug intake.
Area under the plasma concentration-time curve from time 0 to t (AUC0-t)
Pharmacokinetics - AUC0-inf
Time frame: From 0 hours after each drug intake (extrapolated to infinity).
Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf)
Pharmacokinetics - AUCextr
Time frame: From 0 hours after each drug intake (extrapolated to infinity).
Extrapolated AUC defined as (AUC0-inf - AUC0-t)/AUC0-inf
Pharmacokinetics - t1/2
Time frame: From 0 to 24 hours after each drug intake.
Elimination half-life (t1/2)
Pharmacokinetics - kel
Time frame: From 0 to 24 hours after each drug intake.
Elimination constant (kel)
Pharmacokinetics - MRT
Time frame: From 0 to 24 hours after each drug intake.
Mean residence time (MRT)
Pharmacokinetics - Vd
Time frame: From 0 to 24 hours after each drug intake.
Volume of distribution
Pharmacokinetics - CL
Time frame: From 0 to 24 hours after each drug intake.
Clearance (CL)
Pharmacokinetics - number of terminal timepoints
Time frame: From 0 to 24 hours after each drug intake.
Number of points in the terminal logarithmic phase used to estimate the terminal elimination rate constant

55 secondary outcomes

Adverse event type
Time frame: From screeninig (days -14 to -1) to the end of study (day 15 ± 1)
Adverse event number
Time frame: From screeninig (days -14 to -1) to the end of study (day 15 ± 1)
Adverse event severety
Time frame: From screeninig (days -14 to -1) to the end of study (day 15 ± 1)
Drop-outs associated with adverse events
Time frame: From screeninig (days -14 to -1) to the end of study (day 15 ± 1)
Volunteer complaints
Time frame: From screeninig (days -14 to -1) to the end of study (day 15 ± 1)
Physical examination results - cardiovascular system
Time frame: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Physical examination results - respiratory system
Time frame: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Physical examination results - digestive tract
Time frame: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Physical examination results - endocrine system
Time frame: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Physical examination results - musculoskeletal system
Time frame: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Safety and Tolerability: physical examination results - nervous system
Time frame: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Physical examination results - sensory systems
Time frame: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Physical examination results - skin/visible mucous membranes
Time frame: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Vital signs - systolic blood pressure
Time frame: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Vital signs - diastolic blood pressure
Time frame: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Vital signs - heart rate
Time frame: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
Vital signs - body temperature (Celsius temperature scale)
Time frame: Screeninig (days -14 to -1), day -1 to 2, day 7 to 9, day 15 ± 1
12-lead electrocardiogram (ECG) - heart rate
Time frame: Screeninig (days -14 to -1), day 1, 2, 8, 9, 15 ± 1
12-lead electrocardiogram (ECG) - PQ interval
Time frame: Screeninig (days -14 to -1), day 1, 2, 8, 9, 15 ± 1
12-lead electrocardiogram (ECG) - QRS complex
Time frame: Screeninig (days -14 to -1), day 1, 2, 8, 9, 15 ± 1
12-lead electrocardiogram (ECG) - corrected QT interval
Time frame: Screeninig (days -14 to -1), day 1, 2, 8, 9, 15 ± 1
Clinical blood test - hemoglobin
Time frame: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - hematocrit
Time frame: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - red blood cell count
Time frame: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - platelet count
Time frame: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - leukocyte count
Time frame: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - erythrocyte sedimentation rate
Time frame: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - myelocytes
Time frame: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - band neutrophils
Time frame: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - segmented neutrophils
Time frame: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - eosinophils
Time frame: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - basophils
Time frame: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - monocytes
Time frame: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Clinical blood test - lymphocytes
Time frame: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Urinalysis - specific gravity
Time frame: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Urinalysis - color
Time frame: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Urinalysis - transparency
Time frame: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Urinalysis - pH
Time frame: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Urinalysis - protein
Time frame: Screeninig (days -14 to -1), day 2, 9, 15 ± 1
Urinalysis - glucose
Time frame: Screeninig (days -14 to -1), day 2, 9, 15 ± 1

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2025.
Individual participant dataSharing planned: No

Related trials for Pharyngitis

Not yet recruiting
Intracuff Dexmedetomidine Versus Alkalinized Lidocaine for Peri-Extubation Cough and Hemodynamic Responses in Elderly Patients
Airway Complication of Anesthesia, Hemodynamic Instability
RecruitingPhase 4
A Single Dose of Intravenous Penicillin as an Adjunct to Oral Penicillin in the Treatment of Acute Tonsillitis, Peritonsillar Phlegmon, and Peritonsillar Abscess
Acute Tonsillitis, Peritonsillar Abscess
Recruiting
Pharyngeal Mucosal Conditioning to Prevent Postoperative Sore Throat in Septoplasty Patients With Severe Nasal Obstruction
Postoperative Sore Throat, Nasal Obstruction
RecruitingObservational study
A Multicenter Evaluation of SalivIQ™ Strep A for Detecting Group A Streptococcus From Saliva and Throat Swabs in Patients With Acute Pharyngitis
Streptococcal Pharyngitis, Group A Streptococcal Infection
Not yet recruiting
Enhanced Telemedicine in Primary Care for Acute Respiratory Tract Infections Study
Acute Respiratory Tract Infection, Ear Infection

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

Limited Liability Company "Research Center Eco-Safety"

Saint Petersburg, Russia

+7-812-500-52-03

dedkova_va@ecosafety.ru

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Grammidin neo and Grammidin, a metered dose topical spray in people with Pharyngitis, run by Valenta Pharm JSC at 1 site in Russia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 41 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 10 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pharmacokinetics - Cmax (time frame: From 0 to 24 hours after each drug intake.). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06859281.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2025.